ESR1 and breast cancer: The phase III MONALEESA-3 trial used a combination of ribociclib and fulvestrant in advanced ER+/HER2 breast cancer demonstrated an increased PFS (progression-free survival) (Slamon et al., 2018) and an improved OS compared with fulvestrant alone (Slamon et al., 2019).